EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Deletion or immunotherapeutic blockade of FcγRIIb (CD32b) impairs α-Syn propagation in vivo

James M Hennegan, Michael J Hurley, Matthew Colley, Kerry L Cox, Leon R Douglas, Patrick J Duriez, Robert J Oldham, Mark S Cragg, Björn Frendéus, Ali Roghanian, Jessica L Teeling

Acta Neuropathologica · 2026

DOI: 10.1007/s00401-026-03082-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Neuropathologica, 2026. Verfasst von James M Hennegan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Experimental NeuroImmunology, School of Biological Sciences, Faculty of Environmental and Life Sciences, University of Southampton, Southampton Gener…. Hauptthemen laut MEDLINE: Receptors, IgG, alpha-Synuclein, Brain, Parkinson Disease. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wessex Medical Research, Gerald Kerkut Charitable Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson’s disease (PD), the most prevalent neurodegenerative movement disorder, is characterised by widespread alpha-synuclein (α-Syn) pathology in the brain and the progressive degeneration of nigrostriatal dopaminergic neurons. Experimental and clinicopathological data support a templated, prion-like component to α-Syn spread; however, the cellular mechanisms governing fibril uptake and intercellular transmission remain incompletely defined. Fc gamma receptor IIb (FcγRIIb or CD32b), the sole cross-species inhibitory Fcγ receptor, has been implicated in α-Syn internalisation in vitro, though its contribution to α-Syn propagation in vivo is not well established. Here, we examine the role of FcγRIIb in α-Syn seeding, propagation, and neurotoxicity in vivo using the preformed fibril (PFF) α-Syn intracranial injection model in mice. Genetic ablation of murine FcγRII reduced phosphorylated α-Syn (pα-Syn) burden and anatomical distribution across multiple brain regions at 90 days post-PFF injection, consistent with impaired development of Lewy-like pathology. Attenuated pα-Syn pathology was accompanied by reduced microglial reactivity, preservation of nigrostriatal dopaminergic integrity, and protection from PFF-associated motor and exploratory deficits. In parallel, pharmacological blockade of human (h) FcγRIIb using monoclonal antibodies reduced acute-phase pα-Syn accumulation in hFcγRIIb-transgenic mice following PFF challenge. Collectively, these findings identify FcγRIIb as a critical regulator of α-Syn propagation in vivo and support receptor-targeted blockade as a mechanistically distinct and therapeutically tractable strategy for modifying disease progression in PD and related α-synucleinopathies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, IgGalpha-SynucleinBrainParkinson DiseaseAnimalsMiceHumansMice, Inbred C57BLMice, TransgenicMice, KnockoutImmunotherapyDisease Models, AnimalMicrogliaMale

Stichwörter der Autor:innen

FcγRIIbIn vivoMonoclonal antibodiesPFF α-SynParkinson’s diseasePropagation

Substanzen

Receptors, IgGalpha-SynucleinFc gamma receptor IIB

Autor:innen und Institutionen

  • Experimental NeuroImmunology, School of Biological Sciences, Faculty of Environmental and Life Sciences, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK.
  • Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK.
  • Parkinson's UK, London, UK.
  • Curve Therapeutics, Southampton Science Park, Southampton, SO16 7NS, UK.
  • Institute for Life Sciences, University of Southampton, Highfield, Southampton, UK.
  • BioInvent International AB, Solvegatan 41, 22370, Lund, Sweden.

Förderung

  • Wessex Medical Research
  • Gerald Kerkut Charitable Trust

Zitieren

APA

Hennegan, J. M., Hurley, M. J., Colley, M., Cox, K. L., Douglas, L. R., Duriez, P. J., Oldham, R. J., Cragg, M. S., Frendéus, B., Roghanian, A., & Teeling, J. L. (2026). Deletion or immunotherapeutic blockade of FcγRIIb (CD32b) impairs α-Syn propagation in vivo. Acta Neuropathologica. https://doi.org/10.1007/s00401-026-03082-7

Vancouver

Hennegan JM, Hurley MJ, Colley M, Cox KL, Douglas LR, Duriez PJ, et al. Deletion or immunotherapeutic blockade of FcγRIIb (CD32b) impairs α-Syn propagation in vivo. Acta Neuropathologica. 2026. doi:10.1007/s00401-026-03082-7

BibTeX
@article{Hennegan2026,
  author = {Hennegan, James M and Hurley, Michael J and Colley, Matthew and Cox, Kerry L and Douglas, Leon R and Duriez, Patrick J and Oldham, Robert J and Cragg, Mark S and Frendéus, Björn and Roghanian, Ali and Teeling, Jessica L},
  title = {Deletion or immunotherapeutic blockade of FcγRIIb (CD32b) impairs α-Syn propagation in vivo},
  journal = {Acta Neuropathologica},
  year = {2026},
  doi = {10.1007/s00401-026-03082-7}
}
Kostenlos starten →